Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of HER2-Specific CAR T Cells for Recurrent/Refractory Malignant Glioma
NCT03389230Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Aug 2018
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of HER2(EQ)BBζ + CD19t+ in malignant glioma and glioblastoma (GBM) (3 arms), sponsored by City of Hope. Primary endpoints: Incidence of grade 3 adverse events up to 3 years, Dose limiting toxicities up to 3 years and 1 more. Started Aug 2018; status: active, not recruiting.
02
Drugs
HER2(EQ)BBζ + CD19t+
03
Conditions
malignant gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT03389230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03389230.